Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man

Scandinavian Journal of Gastroenterology

Volumn 32, Issue 6, 1997, Pages 552-555

  Wettergren, A ^b   Maina, P ^b   Boesby, S ^b   Holst, J J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE

Author keywords

Enterogastrone; Gastric acid; Pentagastrin; Peptide YY; Proglucagon

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; PEPTIDE YY; PROGLUCAGON;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID; STOMACH ACID SECRETION;

EID: 0030825449     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529709025098     Document Type: Article

References (25)

1. Ali-Rachedi A, Varndell IM, Adrian TE, Peptide YY (PYY) immunoreativity is costored with glucagon-related immunoreactants in endocrine cells of the gut and pancreas. Histochemistry 1984;80:487-91.
2. Böttcher G, Sjölund K, Ekblad E, Håkanson R, Schwartz TW, Sundler F. Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut. Regul Pept 1984;8:261-6.
3. Solcia E, Riocca R, Capella C. Glucagon and PP-related peptides in intestinal L-cells and pancreatic/gastric A or PP cells. Possible interrelationships of peptides and cells during evolution, fetal development and tumor growth. Peptides 1985; 6:233-9.
4. Böttcher G, Alumets J, Håkanson R, Sundler F. Co-existence of glicentin and peptide YY in colorectal L-cells in cat and man. An electron microscopic study. Regul Pept 1986;13:283-91.
5. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985;89:1070-7.
6. Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ. Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 1994;43:535-9.
7. Elliot RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993;138:159-66.
8. Layer P, Holst JJ. GLP-1: a humoral mediator of the ileal brake in humans? Digestion 1993;54:385-6.
9. Pappas TN, Chang AM, Debas HT. Peptide YY release by fatty acids is sufficient to inhibit gastric emptying in dog. Gastroenterology 1986;91:1386-9.
10. Allen JM, Fritzpatrick ML, Yeats JC, Darcy K, Adrian TE, Bloom SR. Effect of peptide YY and neuropeptide Y on gastric emptying in man. Digestion 1984;30:255-62.
11. Schjoldager BGT, Mortensen PE, Christiansen J, Ørskov C, Hoist JJ. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in man. Dig Dis Sci 1989;35:703-8.
12. Wettergren A, Schjoldager BGT, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107 amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993;38:665-73.
13. Wettergren A, Petersen H, Ørskov C, Christiansen J, Sheikh SP, Hoist JJ. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagall v induced gastric acid secretion in man. Scand J Gastroenterol 1994;29:501-5.
14. 2: a physiological inhibitor of gastric acid secretion in man. J Endocrinol 1990; 126:169-73.
15. Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987;28:166-70.
16. Hobsley M, Silen W. Use of an inert maker (phenol red) to improve accuracy in gastric acid secretion studies. Gut 1969; 10:787-95.
17. Layer P, Holst JJ, Grandt D, Goebell H. Heal release of glucagon-like peptide-1 (GLP-1): association with inhibition of gastric acid secretion in humans. Dig Dis Sci 1995;40:1074-82.
18. Olsen O, Christiansen J. Inhibition of human gastric acid secretion by peptide YY and secretin. Digestion 1990;47:156-9.
19. Bado A, Cloarec D, Moizo L, Laigneau JP, Bataille D, Lewin MJM. Neurotensin and oxyntomodulin-(30-37) potentitate PYY regulation of gastric acid and somatostatin secretions. Am J Physiol 1993;265:G113-7.
20. Mogard MH, Maxwell VE, Syntnik B, Walsh JH. Regulation of gastric acid secretion by neurotensin in man: evidence against a hormonal role. J Clin Invest 1987;80:1064-7.
21. Schjoldager BTG, Mortensen PE, Myhrcn J, Christiansen J, Holst JJ. Oxyntomodulin from the distal gut: role in regulation of gastric and pancreatic function. Dig Dis Sci 1989;34:1411-9.
22. Wettergren A, Wøjdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in man depends on an intact vagal innervation. Gut. In press.
23. Pappas TN, Debas HT, Taylor IL. The enterogastrone-like effect of peptide YY is vagally mediated in dog. J Clin Invest 1986;77: 49-53.
24. Nauck M, Ettler R, Niederreicholz U, Ørskov C, Holst JJ, Schmiegel W. Inhibition of gastric emptying by GLP-1 (7-36 amide) or (7-37): effects on postprandial glycemia and insulin secretion. Gut 1995;37 Suppl 2:A124.
25. Adrian TE, Savage AP, Sagor GR, Allen JM, Bacarese-Hamilton AJ, Tatemoto K, et al. Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 1985;89:494-9.